SNBP News and Press, Sun BioPharma Inc From 04/03/20

MINNEAPOLIS, MN, April 03, 2020 (GLOBE NEWSWIRE) --  Sun BioPharma, Inc. (OTCQB: SNBP), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer, today announced it will pause enrollment in its ongoing clinical trial of S...

Enrollment completed in fourth cohort of Phase 1a/1b trial of SBP-101 in pancreatic cancer; expansion cohort initiated Interim Phase 1 data presented at ASCO GI meeting demonstrated tolerability and tumor response in metastatic pancreatic cancer treatment-naïve patients MINNE...

MINNEAPOLIS, Jan. 28, 2020 (GLOBE NEWSWIRE) --  Sun BioPharma, Inc. (OTCQB: SNBP), a clinical-stage biopharmaceutical company developing disruptive therapeutics for the treatment of people with pancreatic cancer, today announced the initiation of a search for a Chief Executive Officer ...

SBP-101 was well tolerated in combination with gemcitabine and nab-paclitaxel Objective Response Rate (ORR) was 62% by RECIST criteria Study expansion in patients with pancreatic cancer planned to begin in Q2 SAN FRANCISCO, Jan. 24, 2020 (GLOBE NEWSWIRE) -- Sun BioPharma, Inc. (OTCQB...

MINNEAPOLIS, Dec. 23, 2019 (GLOBE NEWSWIRE) -- Sun BioPharma, Inc. (OTCQB: SNBP), a clinical-stage biopharmaceutical company developing disruptive therapeutics for the treatment of people with pancreatic cancer, today announced that an abstract describing Phase 1 clinical data for SBP-101...

Sun BioPharma ( OTCQB:SNBP ): Q3 GAAP EPS of -$0.23. More news on: Sun BioPharma, Inc., Earnings news and commentary, Tech stocks news, , Read more ...

Enrollment in Third Cohort of the PDA Combination Study completed; Fourth Cohort planned New U.S. sites added in anticipation of further clinical development Company raised $3.1 million in new capital MINNEAPOLIS, Nov. 13, 2019 (GLOBE NEWSWIRE) -- Sun BioPharma, Inc. (OTCQB: SNBP), a ...

Enrollment in Third Cohort of PDA Combination Study is Encouraging                                Preliminary Efficacy Signals Improve with New Data Regarding Second Cohort Entire $2.3 million Owed under Con...

Preliminary Efficacy Signals Seen with SBP-101 Administered in Combination with Gemcitabine and Nab-paclitaxel DSMB Approves Enrollment of 3 rd and Final Cohort MINNEAPOLIS, July 22, 2019 (GLOBE NEWSWIRE) -- Sun BioPharma, Inc. (OTCQB: SNBP), a clinical stage biopharmaceutical ...

Sun BioPharma ( OTCQB:SNBP ): Q1 GAAP EPS of -$0.31. More news on: Sun BioPharma, Inc., Earnings news and commentary, Tech stocks news, , Read more ...